abbvie glp 1 Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic abbvie glp-1 receptor agonists weight

Recently, a new class of drugs, based on GLP-1, are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity.

Suggested Use: Take 1 capsule 3 times daily, ideally before meals, as part of a balanced health routine

Review our note about shipping this product* Increases GLP-1 naturally* *Based on preclinical studies Formulated with: Akkermansia muciniphila generates the postbiotics propionate and p9 which induce GLP-1 production

However, sudden visual loss, a new blind area or rapidly worsening eyesight requires emergency evaluation

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity

Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as GLP-1 receptor agonist, diabetic retinopathy, glaucoma, age-related macular degeneration, ocular disease, and neuroprotection. The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases